rs137852912 — PCSK9 D374Y

PCSK9 D374Y — The Gain-of-Function Mutation That Makes Cholesterol Drugs Work Harder

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a liver-secreted enzyme whose normal job is to degrade LDL receptors¹¹ LDL receptors
LDL receptors (LDLR) are proteins on liver cell surfaces that capture and remove LDL cholesterol from the bloodstream. Each receptor cycles between the surface and the interior roughly once every 10 minutes. PCSK9 intercepts them inside the cell and routes them to destruction instead of recycling. after they have been internalized. The D374Y variant strips that regulatory restraint: the mutant PCSK9 protein binds LDLR with 10-25-fold higher affinity, causing near-complete LDL receptor depletion from the liver, sky-high LDL cholesterol, and some of the earliest-onset atherosclerosis ever described in a monogenic human disease.

PCSK9 gain-of-function mutations were first discovered by Abifadel et al. in 2003 as the third causal gene for autosomal dominant hypercholesterolemia. The D374Y mutation specifically was identified by Timms et al., 2004²² Timms et al., 2004
Timms KM et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004; 114:349-353. through mutation screening of a large Utah kindred in whom familial hypercholesterolemia could not be explained by LDLR or APOB mutations.

The Mechanism

At position 374 of PCSK9, aspartate (Asp) normally forms a hydrogen bond with His306 in the EGF-A domain of the LDL receptor — but only at the acidic pH of endosomes, providing the tight binding needed to route the receptor to lysosomal destruction. The D374Y substitution replaces aspartate with tyrosine. As shown in the crystal structure by Cunningham et al., 2007³³ crystal structure by Cunningham et al., 2007
Cunningham D et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 2007;14:413-419., tyrosine at 374 maintains a hydrogen bond with His306 at both neutral and acidic pH — eliminating the pH switch that normally limits PCSK9's grip on the receptor. The result is 10-25-fold increased binding affinity and near-complete LDLR degradation.

The mutant PCSK9 is so effective at binding LDLR that it is cleared more rapidly from plasma than wild-type PCSK9 — carriers paradoxically have lower plasma PCSK9 levels than expected for their degree of hypercholesterolemia, because the mutant protein is rapidly pulled out of circulation by LDLR-mediated uptake before it degrades them. Lambert et al., 2009⁴⁴ Lambert et al., 2009
Lambert G et al. Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9. Clin Chem 2009;55:2153-2161. demonstrated this in a comparative study: measuring plasma PCSK9 levels will underestimate disease severity in D374Y carriers and is unreliable as a screening tool for this variant.

Beyond cholesterol clearance, a 2025 study in transgenic mice⁵⁵ 2025 study in transgenic mice
PCSK9 with a gain of function D374Y mutation aggravates atherosclerosis by inhibiting PPARα expression. Sci Rep 2025. showed that D374Y PCSK9 inhibits PPARα⁶⁶ PPARα
Peroxisome proliferator-activated receptor alpha — a nuclear receptor that promotes fatty acid oxidation and anti-inflammatory signaling in macrophages. Reduced PPARα activity promotes foam cell formation and arterial inflammation. expression in arterial macrophages, accelerating plaque formation through both lipid accumulation and inflammatory mechanisms.

The Evidence

The most striking clinical data comes from Naoumova et al., 2005⁷⁷ Naoumova et al., 2005
Naoumova RP et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 2005; 25:2654-2660., who followed 13 D374Y carriers from 4 unrelated British families for up to 30 years:

• Total cholesterol: 13.6 ± 2.9 mmol/L (527 ± 112 mg/dL) — compared to 9.6 mmol/L for severe LDLR mutation carriers
• LDL cholesterol: typically 300-400 mg/dL; levels that LDLR mutations rarely achieve
• Coronary artery disease onset: 35.2 ± 4.8 years — more than 10 years earlier than LDLR-FH patients (46.8 years)
• Treatment response: partially responsive to high-dose statins, but many required combination therapy including LDL apheresis

PCSK9 inhibitors (evolocumab, alirocumab) are highly effective for most FH patients, but the D374Y mutant presents a pharmacological challenge. Anti-PCSK9 antibodies show approximately 2-fold lower binding affinity to the D374Y variant than to wild-type PCSK9, because the mutation changes the antibody-binding epitope near position 374. Clinical experience suggests that PCSK9 inhibitors still provide meaningful LDL reduction in D374Y carriers, but the response may be attenuated compared to LDLR-mutation FH patients. Inclisiran (siRNA-based PCSK9 silencing) targets PCSK9 mRNA rather than the protein, so its mechanism is unaffected by D374Y's altered protein structure — it may be more effective than antibody-based inhibitors for this specific mutation.

In a Turkish FH cohort study⁸⁸ Turkish FH cohort study
Akın M et al. PCSK9 gain-of-function mutations (R496W and D374Y) and clinical cardiovascular characteristics in a cohort of Turkish patients with familial hypercholesterolemia. Anatol J Cardiol 2017;18:339-345., D374Y was detected in 5% of FH patients, and carriers had more severe cardiovascular phenotypes than patients with R496W (another GOF variant), including 3.4-fold higher triglycerides and younger age at coronary events.

Practical Actions

If you carry the D374Y variant (GT genotype), you have autosomal dominant familial hypercholesterolemia-3 (FHCL3, OMIM 603776) — a medical diagnosis that requires immediate specialist evaluation and lifelong aggressive lipid management. The D374Y variant is classified Pathogenic/Likely pathogenic in ClinVar⁹⁹ Pathogenic/Likely pathogenic in ClinVar
ClinVar variation ID 2875, reviewed by multiple submitters with no conflicts. and listed in OMIM as allelic variant 607786.0003.

This is not a risk factor that can be managed by diet alone. The core interventions are: maximum-dose statin therapy (rosuvastatin 40mg/atorvastatin 80mg), ezetimibe co-administration (synergistic with statins for FH), PCSK9 inhibitor therapy (noting that the D374Y mutant protein has reduced antibody affinity, so response monitoring is essential), and LDL apheresis for carriers not achieving target LDL on pharmacotherapy.

LDL-C targets for D374Y carriers are more aggressive than standard FH targets: European Society of Cardiology guidelines recommend LDL-C below 1.4 mmol/L (55 mg/dL) for very high-risk patients. Given average pretreatment LDL of 300-400 mg/dL in D374Y carriers, achieving targets virtually always requires triple therapy (statin + ezetimibe + PCSK9 inhibitor) and often LDL apheresis.

Cascade genetic testing for all first-degree relatives is mandatory — each child and sibling has a 50% chance of inheriting D374Y.

Interactions

D374Y acts through the same pathway as LDLR mutations (FH1, OMIM 143890), but through the opposing mechanism: where LDLR mutations reduce receptor availability by impairing receptor synthesis or function, D374Y accelerates receptor destruction. This means:

• D374Y + LDLR mutation (double heterozygosity): Extremely rare but catastrophic — both receptor production and receptor destruction pathways are simultaneously impaired. The phenotype approaches homozygous FH severity, with LDL-C potentially exceeding 600 mg/dL. Clinical documentation is sparse due to rarity; immediate lipidology referral is required.
• D374Y + PCSK9 LOF variant (rs11591147 R46L): Theoretical antagonism — the R46L loss-of-function variant reduces PCSK9 activity while D374Y increases it. Whether R46L meaningfully attenuates D374Y gain-of-function is uncertain; no published compound heterozygote has been reported. Given D374Y's 10-25-fold affinity increase, a 15-20% activity reduction from R46L would be unlikely to substantially normalize LDL.
• Response to PCSK9 inhibitors: Evolocumab and alirocumab (monoclonal antibodies) have reduced but not absent efficacy against D374Y due to altered epitope binding. Inclisiran (siRNA targeting PCSK9 mRNA) is mechanism-independent of D374Y's protein change and may be the preferred PCSK9-directed therapy for D374Y carriers.